Molecular drug susceptibility testing and strain typing of tuberculosis by DNA hybridization

PLoS One. 2019 Feb 7;14(2):e0212064. doi: 10.1371/journal.pone.0212064. eCollection 2019.

Abstract

In Mycobacterium tuberculosis (Mtb) the detection of single nucleotide polymorphisms (SNPs) is of high importance both for diagnostics, since drug resistance is primarily caused by the acquisition of SNPs in multiple drug targets, and for epidemiological studies in which strain typing is performed by SNP identification. To provide the necessary coverage of clinically relevant resistance profiles and strain types, nucleic acid-based measurement techniques must be able to detect a large number of potential SNPs. Since the Mtb problem is pressing in many resource-poor countries, requiring low-cost point-of-care biosensors, this is a non-trivial technological challenge. This paper presents a proof-of-concept in which we chose simple DNA-DNA hybridization as a sensing principle since this can be transferred to existing low-cost hardware platforms, and we pushed the multiplex boundaries of it. With a custom designed probe set and a physicochemical-driven data analysis it was possible to simultaneously detect the presence of SNPs associated with first- and second-line drug resistance and Mtb strain typing. We have demonstrated its use for the identification of drug resistance and strain type from a panel of phylogenetically diverse clinical strains. Furthermore, reliable detection of the presence of a minority population (<5%) of drug-resistant Mtb was possible.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • DNA, Bacterial / genetics
  • DNA, Bacterial / metabolism*
  • Humans
  • Microbial Sensitivity Tests
  • Multiplex Polymerase Chain Reaction
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / genetics*
  • Mycobacterium tuberculosis / isolation & purification
  • Nucleic Acid Hybridization
  • Polymorphism, Single Nucleotide
  • Tuberculosis / microbiology
  • Tuberculosis / pathology*

Substances

  • Antitubercular Agents
  • DNA, Bacterial

Grants and funding

The authors would like to acknowledge funding for this project provided by startup funds from UCF to KHR. Jef Hooyberghs acknowledges funding of a travel grant by FWO (K226314N). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.